The literature suggests that NOP2 is highly expressed in prostate cancer, gallbladder cancer, and lung adenocarcinoma, while upregulated YBX1 plays a significant protumourigenic role in breast, renal, and gastric cancer [34–38]. The gene discussed is NOP2; the disease is prostate carcinoma.